Is Visoluten FDA approved?
No. This profile records Visoluten as not FDA approved and for research use only.
MORE CONTEXT ›
Review the regulatory and source details on this page for the current context.
Longevity CATEGORY
Visoluten
THE EYE PROTECTOR
A-5 Eye Bioregulator Peptide
Visoluten is a bioregulator peptide derived from eye tissue that supports retinal and optic nerve health. It protects photoreceptors, reduces eye inflammation, and stabilizes the blood-retinal barrier. Ideal for people with age-related vision changes, macular degeneration, or those wanting to protect their eyes from screen strain.
Visoluten
Visoluten
Visoluten
Visoluten Evidence Snapshot
How these guides are reviewed
REGULATORY STATUS
Not FDA approved · research use only
DOSING GUIDANCE
Reviewed by our clinical team
LINKED EVIDENCE
1 research sources
CONTENT UPDATED
May 8, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
Quick Answers About Visoluten
What dose does The Peptide App Clinical Team recommend for Visoluten?
Dose: 20 mg orally or sublingually each morning.
MORE CONTEXT ›
Schedule: daily. Cycle: 4 weeks on, 12 weeks off. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
What research supports this Visoluten guide?
This guide links to 1 curated or current research sources.
MORE CONTEXT ›
Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Studied Effects & Mechanisms
Visual Cycle Support
Enhances RPE65 and CRALBP for rhodopsin recycling and light sensitivity
Antioxidant Protection
Increases SOD2 and catalase in photoreceptors to prevent oxidative damage
Barrier Stabilization
Upregulates tight junction proteins to protect blood-retinal barrier
People with age-related macular degeneration
Those with glaucoma or elevated eye pressure
Anyone with dry eye syndrome
People experiencing screen-related visual stress
Those wanting to protect vision during aging
Visoluten Research
Live research temporarily unavailableThe live research feed did not return papers for this page. The curated references below remain available for crawlable source context.
RESEARCH REFERENCES